Chronic Heart Failure (CHF), Iron Deficiency
Conditions
Keywords
oxidative stress, exercise tolerance, intravenous route (IV), intramuscular route (IM)
Brief summary
ERADAL-HF is a double blinded, multi-centre, prospective, randomized, three arm study, enrolled ambulatory patients with chronic heart failure \[New York Heart Association (NYHA) class II/III\], with iron deficiency \[defined as ferritin \<100 ng/mL, or ferritin 100-300 ng/mL if transferrin saturation (TSAT) \<20%\] and haemoglobin (Hb) \< 15 g/dL. Patients were randomized 1:1:1 to treatment into three arms: a first group treated with intravenous iron supplementation, a second treated by intramuscular iron supplementation and the third one which have received placebo. These patients were followed-up during a period of 04 weeks. The aim of this study is to assess the short term effect of parenteral iron supplementation on exercise tolerance and oxidative stress in patients with stable chronic heart failure and iron deficiency
Detailed description
ERADAL-HF is a double blinded, multi-centre, prospective, randomized, three arm study, enrolled ambulatory patients with chronic heart failure \[New York Heart Association (NYHA) class II/III\], with iron deficiency \[defined as ferritin \<100 ng/mL, or ferritin 100-300 ng/mL if transferrin saturation (TSAT) \<20%\] and haemoglobin (Hb) \< 15 g/dL. Patients were randomized 1:1:1 to treatment into three arms: a first group treated with intravenous iron supplementation, a second treated by intramuscular iron supplementation and the third one which have received placebo. These patients were followed-up during a period of 04 weeks. The aim of this study is to assess the short term effect of parenteral iron supplementation on exercise tolerance and oxidative stress in patients with stable chronic heart failure and iron deficiency in a sub-Saharan Africa. In addition, it will also try to evaluate its effectiveness using the intramuscular route and this with a simplified administration scheme.
Interventions
DRUGFerric polymaltose hydroxide complex IM
Intervention will consisted of the administration for the IM route. Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.
DRUGIron Sucrose IV
Intervention will consisted of the administration for the IV route. -The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14.
OTHERSaline solution
100 ml i.v. of normal saline administered at Day 0 and at day 14.
Sponsors
CN NGANOU-GNINDJIO, MD, MSc
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
21 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Subjects with stable CHF (NYHA II/III functional class) * Screening serum ferritin \<100 ng/mL or 100-300 ng/mL with transferrin saturation \<20%. * Haemoglobin \< 15 g/dl ; * On optimal background therapy (as determined by the investigator) for at least 4 weeks with no dose changes of heart failure drugs during the last 2 weeks (with the exception of diuretics). In general, optimal pharmacological treatment should include an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker and a beta blocker unless contraindicated or not tolerated and diuretic if indicated. * Subject must be capable of completing the 6MWT * Before any study-specific procedure, the appropriate written informed consent must be obtained.
Exclusion criteria
* Subject has known sensitivity to any of the products to be administered during dosing. * History of acquired iron overload. * History of erythropoietin-stimulating agent, i.v. iron therapy, and/or blood transfusion in previous 6 weeks prior to randomization. * Oral iron therapy at doses \>100 mg/day in previous 1 week prior to randomization. Note: ongoing use of multivitamins containing iron \<75 mg/day is permitted. * Body weight ≤35 kg. * Exercise training programme(s) in the 3 months prior to screening or planned in the next 6 months. * Chronic liver disease (including active hepatitis) and/or screening alanine transaminase or aspartate transaminase above three times the upper limit of the normal range * Subject will not be available for all protocol-specified assessments.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Variation in 6-minute walk test (6MWT) distance | 4 weeks | Variation in 6MWT in meter distance from the baseline to week 4. By using pedometer |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in quality of life assessed by the Minnesota Living With Heart Failure Questionnaire (MLWHFQ) | 4 weeks | Minnesota Living With Heart Failure Questionnaire score at Week 4 adjusted for baseline |
| Change in serum concentration of anti-oxidant markers: Reduced Glutathione (micromol) | 4 weeks | Change in serum concentration of anti-oxidant markers from baseline to week 4. By spectrophotometer |
| Change in serum concentration of oxidant marker: Malondialdehyde (micromol/l) | 4 weeks | Change in concentration of oxidant marker from baseline to week 4. By spectrophotometer |
| Change in serum ferritin concentration | 4 weeks | Change in serum ferritin concentration (micromol/l) level from baseline to week 4. By immunology |
| Cost-effectiveness by using the Incremental Cost-effectiveness Ratio (ICER) | 4 weeks | Cost-effectiveness by using the ICER questionnaire between the IV and the IM route |
| Standard safety assessments | 4 weeks | Standard safety assessments: adverse events by questionnaires |
| Change in Left Ventricle Ejection Fraction by Simpson method | 4 weeks | Change in Left Ventricle Ejection Fraction (%) by Simpson method on echocardiography from baseline to week 4 |
Countries
Cameroon
Outcome results
None listed